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I. Introduction
Medicine has had a very significant impact on my life. When I just 5 years old,
my mom was diagnosed with breast cancer. Having beaten the disease, we felt that we, as
a family, were in the clear. Fast-forward to the beginning of high school, and my world
was changed. My dad had three surgeries, one hip replacement and two to replace
femoral hairline fractures, in three months. Our lives never really went back to “normal”,
and I have not seen my dad walk without some sort of assistance since. So my
relationship with medicine and with doctors has been somewhat complicated. I have seen
the wonders they can do, which I will discuss more later in this chapter. I have also seen
how it can fail and change lives not necessarily for the better. There are many factors that
determine the outcomes of certain diseases, but I believe that one of the most important is
the doctor-patient relationship. There are also many factors that can affect that
relationship, one of them being direct-to-consumer (DTC) drug advertisements. However,
before explicitly discussing how DTC advertisements affect doctor-patient relationships,
it is important to give some context as to how the medical field has evolved to what we
know it to be today. In doing so, we will have the necessary foundation to understand
how and why DTC advertisements affect doctor-patient relationships.
To begin, medicine, or rather the study and practice of medicine, has existed in
every period of history where people have had to deal with disease and illness and had to
find a way of resolving those ailments. How each period coped with its circumstances is a
reflection of the time and the culture. Although some historians include ancient Egypt in
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their discussions on the history of medicine, I will omit that period and begin with ancient
Greece as it is more associated with the Western medical tradition. The most prominent
figure to come out of ancient Greece was Hippocrates, who is widely known as the
“Father of Medicine.” He wrote a collection of texts and essays that have led to the
tradition of Hippocratic medicine, which is largely the foundation of Western medicine.
This tradition greatly emphasizes the patient rather than the disease itself, and it
established the well known motto “At least do no harm” (Magner, 1992). This motto is
still recited by today’s physicians showing the lasting influence Hippocrates had. Along
with explaining the role of the physician, Hippocrates was one of the first people to not
blame the gods for the occurrence of the diseases because he believed that these diseases
were a part of a natural process. Recognizing that there was not a causal relationship
between the gods and disease is what Hippocrates believed made one a true physician
(Magner, 1992). That is not to say Hippocrates did not believe in the gods, but he
understood that nature played a pivotal role in medicine (Magner, 1992). With the insight
of Hippocrates, the practice of medicine transitioned to a more rational way of thinking
about disease. However, as time progressed into the Middle Ages, the Hippocratic
tradition fell somewhat out of favor.
Medicine in the Middle Ages can be characterized by a complex interplay
between medicine and religion, more specifically Christianity. Because Christianity was
so prevalent through society, there was a shift in how people viewed the body and how it
should be treated. The Greeks desired a healthy human body while Christians maintained
a somewhat repugnant view of the body. That is, Christians could not view the body as
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something to be desired, especially in a sexual context. However, they did believe that it
deserved some care and respect because the body houses the soul, which is given by God.
These beliefs led to a different way of healing illnesses. It involved prayers, exorcisms,
etc. while Hippocratic medicine utilized empirical practices such as drugs, diet, and
simple surgeries. Thus, there was clear difference between religious medicine and human
medicine. Religious medicine relied on prayers, exorcisms, etc. while human medicine
valued the use of drugs and simple surgical operations (Magner, 1992). Although
practicing human medicine was not looked down upon, it had an unstable relationship
with the Church, and that relationship had to be acknowledged. As time continued on,
medieval scholars determined medical studies to be “an integral part of Christian
wisdom” (Magner, 1992). That is, if all knowledge came from God, that included
medical knowledge, and it began to be seen as a more serious subject to be studied. Thus,
medical education was formally established in universities, but very few practitioners
actually had university training. Despite this, in the Middle Ages, began the process of
establishing medicine as a formal profession that included an education, standardized
curriculum, licensing, and legal regulation. It was also during this time that the first
“hospitals” were established. This term is used loosely because our current organization
of hospitals is vastly different than the one used in the Middle Ages (Magner, 1992).
Medieval hospitals were established for largely religious reasons and not scientific ones
(Figure 1).
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Figure 1. Image showing the role Christianity played in medicine during the middle ages
(Medieval Life, 2013).

Medicine during ancient Greece utilized the practices established by Hippocrates
while medicine during the Middle Ages was largely influenced by Christian tradition, but
for both time periods, the treatments involved were not based on scientific reason. The
Scientific Revolution was the beginning of the integration of medicine and science.
Perhaps the most well known figure to come out of the Scientific Revolution, with
regards to medicine, is William Harvey. Harvey discovered the circulation of the blood
and changed the way people thought about the heart and the movement of blood
(Magner, 1992). The Scientific Revolution also saw the use of phlebotomy and blood
transfusions; although, neither of those practices would be perfected until an
understanding of the immune system emerged (Figure 2). Nevertheless, the Scientific
Revolution saw an increase in experimentation and began the process of using science to
develop medical techniques. Although some of the techniques used were crude and
4

ineffective, it showed the interest physicians had in learning more about the body and
finding ways to treat its illnesses using more effective means. These practices lay the
foundation for more scientific research and developing improved techniques to treat
different illnesses.

Figure 2. William Harvey discovered
the circulation of during the Scientific
Revolution (Schultz, 2002).

We can now enter into the modern era of medicine with scientists Louis Pasteur
and Robert Koch leading the way. It was not until our understanding of microorganisms
that scientists were able to develop treatments we are more familiar with today, and both
Pasteur and Koch were instrumental in that understanding. Pasteur integrated several
fields of science and is credited for identifying the role that microbes play in the
fermentation process. Through these experiments, Pasteur became interested in
disproving the spontaneous generation theory (Berche, 2012). In trying to show that
microbes do not spontaneously generate in sterile medium, Pasteur developed the sterile
techniques that gave way to modern microbiology and surgery (Magner, 1992). Pasteur
was also a pioneer in the development of vaccines. Before developing a vaccine, he
5

became interested in infectious diseases during an epidemic of silkworms in southern
France between 1865 and 1870 (Berche, 2012). Shortly thereafter, in 1878, Pasteur
discovered a vaccine against fowl cholera. Like Pasteur, Koch, too, became interested in
scientific research and began his work with Bacillus anthracis, more commonly known
as anthrax. He discovered that bacteria could be cultured outside of the organism it was
discovered in (Magner, 1992). He also discovered the bacteria that cause tuberculosis.
Pasteur confirmed the causative role of B. anthracis (Berche, 2012). While Pasteur would
go on to searching for a rabies vaccine, Koch began to research wound infection, and
soon tuberculosis. The discoveries made by Pasteur and Koch, in conjunction with the
germ theory, highlighted the idea that diseases could be controlled, and perhaps even
stopped. It had implications for public health and triggered government-paid investigators
to determine the sources of infection. It created a government-regulated medical
profession, and “hospitals became one of the chief sites for scientific medicine in the
nineteenth and twentieth centuries” (Jackson, 2011). In Western Europe, between 1883
and 1911, countries also passed national health insurance legislation, and shortly
thereafter, there were regulations for food and drugs in the medical market (Jackson,
2011). As time has continued into the present age, a medical field with more government
regulations was more commonplace. In regards to the United States, Jackson (2011)
writes that the U.S. has become dependent on “big science” to solve its health issues,
possibly because the U.S. does not have a national health care system, and thus, health
insurance companies have become a defining characteristic of American medicine.
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The history of medicine is long and complex, and a few traditions of medicine
have been left out to provide clarity and to provide a more relevant history of the Western
tradition of medicine that is the backbone of the today’s tradition. Not every event in the
history of medicine is still relevant today, but many themes are still relevant and have
evolved into the practices that we are familiar with. These practices include treatments,
scientific research, and patient-care. Thus, it is the medical practices of today that have
sparked my interest in the field and that made me want to become a physician.
Looking back, I cannot pinpoint the exact moment that I wanted to become a
physician. Rather, it was a succession of events that ultimately led me to the path that I
am on today. One of those major events was the day my nephew, Ethan, was born. Ethan
was born with a rare genetic disorder known as urea cycle disorder; he was diagnosed
within 48 hours of being born. Only 15 at the time, I could have never predicted the
impact that Ethan would ultimately have on my life. At 3 months old, he received a liver
transplant from UCLA Ronald Regan Medical Center. Although there were other health
complications along the way, today, he is healthy and as rambunctious as any 5 year old
can get.
He is ultimately my inspiration for becoming a physician. I aspire to be like one
of the physicians on the amazing team of physicians that provided Ethan with the best
possible care as they were able to perform under dire circumstances. At all times, they
remained calm and composed and were able to provide the best possible care for Ethan.
Ultimately, that is what physicians should aim to do. Physicians should provide the best
possible care even under unforeseen circumstances. This belief has been furthered
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solidified by my time spent volunteering in an Emergency Department (ED) in Denver,
Colorado. I saw the physicians providing care in a stressful environment to the best of
their abilities. Often times, the patients are difficult and can be stubborn, which is
expected. Patients are scared coming into the ED. Often, they do not want to be there and
the long waiting time just adds to the anxiety they may already be feeling. Regardless, the
doctors are expected to provide their patients with exceptional care.
Reflecting on these experiences, I began to consider what goes into “exceptional
care.” Does providing the best care only encompass achieving desirable results like a
successful liver transplant? Or is writing a prescription a sufficient requirement for
exceptional care? How much time does a physician need to evaluate, diagnose, and then
treat a patient? It may seem obvious that this would require time; time that develops into
a relationship with the patient, but is it even necessary for doctors to develop
relationships with their patients? These thoughts led me into contemplating what it even
means to be a physician and what his/her roles and duties are to his/her patients.
It became clear to me that the physicians who treated my nephew and those who
work in my ED are practicing care that is ideal, and that care may not the standard but
rather the exception. Doctor-patient relationships are becoming compromised in today’s
society, and I will be examining one particular issue that is compromising that
relationship. Dr. Abramson, a retired family physician sheds light on this issue:
The pressure from my patients to prescribe Celebrex and Vioxx did not let up,
intruding into alliances that had been built up over many years. I tried to explain
that these drugs offered no better relief than the older, less expensive antiinflammatory drugs. I actually started to enjoy the challenge of trying to refocus
my patients’ attention back onto their underlying issues…I did my best to help
them understand that their beliefs about these drugs were being masterfully
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manipulated by the companies’ multipronged marketing efforts, and that these
efforts were being driven far more by the goal of improving the drug companies’
sales than improving patients’ health or comfort. (Abramson, 2004)

Dr. Abramson was a physician for 28 years before he left his practice to write his book,
Overdo$ed America. It tells of the new reality in American medicine; a reality in which
television, magazine, and print advertisements of prescription drugs permeate our
everyday lives. Those advertisements are known as direct-to-consumer drug
advertisements, or DTC advertisements. The Federal Drug Administration (FDA) defines
direct-to-consumer advertisements as “ads [that] are published in magazines and
newspapers that are distributed to a general audience rather than to healthcare providers
such as doctors, nurses, and pharmacists. DTC ads can also be broadcast through
television or radio” (Drug Advertising: A Glossary of Terms, 2016), and huge amounts of
money are being spent on DTC advertisements. Drug companies spent $4.5 billion on
prescription drug TV advertisements (Millman, 2015). With that much money being
poured into these advertisements, one has to wonder if the pharmaceutical companies
have the patients’ best interest at heart. The patients may not realize that their care can be
compromised when there is an overload of drug advertisements giving them insight as to
how physicians should provide care. They may not realize that the drugs being advertised
are being advertised not in the best interest of the patients but in the best interest of the
drug companies.
In today’s world, it is nearly impossible to go anywhere or do anything without
seeing an advertisement. Whether it is for clothes, makeup, or even drugs, they are
everywhere, and it is very difficult to deny the influence that these advertisements have in
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our everyday lives. Patients consume the information from the advertisements, and then
go to their doctor with the information they received. However, not every advertisement
applies to every patient. Doctors have to be able to communicate that not every drugrelated treatment their patients see is going to be effective for whatever problem is being
addressed. Thus, the doctor-patient relationship can be strained if the patient insists on
having that particular drug. It then becomes essential for physicians to evaluate how to
maintain their relationships with patients with the influence of drug advertisements, and
in those situations, it becomes crucial for them to remember what it means to be a
physician.
In my attempt to determine how drug advertisements are affecting doctor-patient
relationships specifically, I will be analyzing, first, what it means to be a physician
providing the best possible care. I will discuss physicians’ roles and duties to their
patients. To aid in this discussion, I will analyze the modern Hippocratic oath that many
physicians recite today after completing their medical education. The oath provides an
ethical outline as to how physicians should care for their patients and gives a more
concrete understanding of the doctor-patient relationship. Once the role of the physician
is fully understood, I can discuss how DTC advertisements are affecting doctor-patient
relationships. After analyzing drug advertisements in today’s society, I will then discuss
what direct-to-consumer drug advertising might look like as medicine begins to evolve
towards personalized medicine and determine how doctor-patient relationships might also
evolve with personalized medicine. Although the overwhelming amount of drug
advertisements in today’s society leads some patients to better communicate with their
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physicians, that communication does not lead to an improvement of the care the patient
receives. Furthermore, those advertisements are resulting in skyrocketing drug prices and
the inability for physicians to provide adequate care to their patients. Therefore, it is
imperative that prescription drug advertisements be removed altogether or have limited
availability to the general public. It is in the best interest of pharmaceutical companies
and physicians to continue to put patient care and overall public health as priority.
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II. Role of the Physician
The issue of drug advertisements brings up fundamental questions on what it
means to be a doctor. Before I begin a discussion on how drug advertisements influence
the care that doctors administer, it is important to begin with what physicians’ roles are in
the first place. There are different components to being a physician, and years of training
are required. However, I will focus specifically on the role of the physician as it is related
to diagnoses and treatments. It is ultimately how physicians develop relationships with
their patients that will influence the diagnoses and treatments of those patients. Doctors
must be compassionate, caring, understanding, and listen openly to their patients.
Although developing these qualities and acting on them is at the discretion of the
individual physician, there is an oath, or a variation of, that all doctors take at the end of
their medical education that can serve as a guideline. The most widely used and wellknown oath is the Hippocratic oath.
The original Hippocratic oath written by Hippocrates himself, is rarely used
today. Instead, the modern oath was written by Louis Lasagna, the then academic dean at
Johns Hopkins University, in 1964 (Eva, 2014). The modern Hippocratic Oath is as
follows:
I swear to fulfill, to the best of my ability and judgment, this covenant:
I will respect the hard-won scientific gains of those physicians in whose steps I
walk, and gladly share such knowledge as is mine with those who are to follow.
I will apply, for the benefit of the sick, all measures which are required, avoiding
those twin traps of overtreatment and therapeutic nihilism.
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I will remember that there is art to medicine as well as science, and that warmth,
sympathy, and understanding may outweigh the surgeon's knife or the chemist's
drug.
I will not be ashamed to say "I know not," nor will I fail to call in my colleagues
when the skills of another are needed for a patient's recovery.
I will respect the privacy of my patients, for their problems are not disclosed to
me that the world may know. Most especially must I tread with care in matters of
life and death. Above all, I must not play at God.
I will remember that I do not treat a fever chart, a cancerous growth, but a sick
human being, whose illness may affect the person's family and economic stability.
My responsibility includes these related problems, if I am to care adequately for
the sick.
I will prevent disease whenever I can, for prevention is preferable to cure.
I will remember that I remain a member of society, with special obligations to all
my fellow human beings, those sound of mind and body as well as the infirm.
If I do not violate this oath, may I enjoy life and art, respected while I live and
remembered with affection thereafter. May I always act so as to preserve the
finest traditions of my calling and may I long experience the joy of healing those
who seek my help. (“Hippocratic Oath”, 2004)
The oath touches on many prevalent aspects of today’s healthcare, but I will only analyze
those lines in which patient care is applicable. The first line I wish to look at states, “I
will apply, for the benefit of the sick, all measures which are required, avoiding those
twin traps of overtreatment and therapeutic nihilism.” Overtreatment is the overuse of
therapy, drugs, and psychotherapy. Therapeutic nihilism is exactly the opposite. It refers
to undertreatment (Mamede & Schmidt, 2014). That is, the body should be able to heal
on its own. Essentially, the oath is stating that there has to be proper balance of how a
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patient is cared for. Letting the body heal on its own is not always the best or the most
responsible mode of action, but overtreatment is just as harmful to the patient.
In regards to the relationship with the patient, the oath states, “I will remember
that there is art to medicine as well as science, and that warmth, sympathy, and
understanding may outweigh the surgeon’s knife or the chemist’s drug.” This line implies
that there is a humanistic approach to medicine. Moving beyond science, “warmth,
sympathy, and understanding” are necessary qualities for a doctor to have. Thus, it is
emphasizing that caring for patients and treating them in a humanistic way is more
important than the science of medicine. Patients are more than just bodies to practice
surgeries on or to supply with drugs; they are people who should be treated as such.
Treating people with warmth and understanding goes beyond solely trying to treat them.
In fact, if treating a patient is actually degrading to who he/she is as person, then
treatment should be avoided altogether.
The aforementioned line plays directly into the lines, “I will remember that I do
not treat a fever chart, or a cancerous growth, but a sick human being, whose illness may
affect the person’s family and economic stability. My responsibility includes these related
problems, if I am to care adequately for the sick.” Caring for a patient extends beyond the
illness itself. Physicians are treating “a sick human being” which implies that there is a
certain standard to how they should be treated. Stating that humans are more than their
illnesses shows a certain respect for not only their bodies but also their humanities.
Furthermore, by stating that the patient’s illness could affect not only his/her family but
its economy as well, implies that the physician is involved in something larger. Anything
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the physician does has implications for the wider community. Therefore, it is necessary
for physicians to think carefully about how they treat their patients and the larger impact
on the patients, their families, and the greater society. If doctors can remember to do this,
then they will be able to treat their patients not only with the appropriate treatments but
also with a respect and dignity that all persons deserve. Doctors go into their profession
with the intentions of healing, but they must remember that it is not just what they are
healing but whom they are healing, the latter superseding the former.
The oath provides an ethical outline as to how physicians should provide care for
their patients. It becomes evident that being a physician extends beyond the scope of
scientific knowledge; it also involves a deep understanding of human nature (Hellín,
2002). Being a doctor extends beyond just knowing the science behind the medicine; it is
also about realizing that the medicine is being applied to real people and should be held
to a higher standard. Doctors must possess a wide array of knowledge and be able to
retain information correctly so as to be of the most use to their patients. It is the best
doctors that can use the knowledge they possess to effectively care for their patients.
However, they must also possess qualities that show that they are understanding of
people and the situations that they are in. There will often be times when patients and
physicians live drastically different lifestyles, but they have to be committed to patient
care regardless of the patients’ lifestyle and value system (Hellín, 2002). Even if doctors
themselves cannot relate to the situation their patients are in, they have to still show that
they care and are willing to do what is necessary to improve the situation. Thus, doctors
also have to be flexible, understanding, and fully committed to their patients. A physician

15

must provide care at all costs if it is in the best interest of the patient. Ultimately, the goal
of the physician is to heal the patient with the understanding that the healing process
encompasses being caring towards and having compassion for the patient.
Establishing a foundation for how patient care should be administered is essential
to providing quality diagnoses and treatment. The first of the two, diagnoses, begins the
process of effective treatment (Taylor, 2015). Diagnosis is defined as “the elucidation of
the cause of heretofore unexplained symptoms, signs, and laboratory/imaging findings”
(Taylor, 2015). Learning to diagnose is a skill that requires a significant amount of
medical knowledge and learning how to apply that medical knowledge on a case-by-case
basis. In order to be successful at that skill, a physician must also have a good memory,
excel at physical examinations, and be an empathetic listener (Taylor, 2015). Of these
skills, being an empathetic listener is perhaps one of the most important qualities.
Patients are often more willing to disclose information to physicians they feel more
comfortable with. It is through listening that a patient’s current problem is discovered.
Combined with the patient’s medical history, an accurate diagnosis is dependent on there
being an intimate relationship between the physician and the patient because the doctors
must know a great deal of information about their patients and about their values (Hellín,
2002). That relationship develops as patients begin to feel more comfortable with their
doctors, and they can begin to feel more comfortable with their doctor if they exhibit the
aforementioned qualities. Furthermore, if there is an increased capacity for
communication between the doctor and the patient, the strength of the doctor-patient
relationship increases as well as the strength of the diagnosis.
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Therefore, communication is essential to the development of doctor-patient
relationship and leads to the most accurate diagnosis. Moreover, utilizing effective
communication skills is becoming increasingly important when delivering the diagnosis
itself. More than ever, there is an emphasis on full disclosure and communication skills in
the medical field (Sisk et al., 2015). The American Hospital Association created “A
Patient’s Bill of Rights” in 1973, and from then on, patients have the right to know every
aspect of their health and medical care regardless of severity (Sisk et al., 2015). Thus,
knowing how to properly communicate about a diagnosis to a patient is becoming
increasingly important. Of course, this is a challenging skill to learn and one that often
improves over time, but it is essential to the discovery and the communicating of a
diagnosis and then ultimately how a physician will treat said diagnosis.
Once a proper diagnosis is given, the physician can provide the best treatment.
There are a myriad of treatments available, but the appropriate treatment must be
administered for the given diagnosis. Many treatments today are administered according
to science-based medicine and clinical guidelines (Taylor, 2015). However, it is possible
that clinical guidelines can disagree, and while remaining aware of clinical guidelines is
important, it is important to treat patients based on “evidence, experience, and clinical
context” (Taylor, 2015). This means that the physician has to be knowledgeable about the
current treatments available and consider any alternatives that might serve the patient
better. When new treatments become available, physicians must also be knowledgeable
about those as well. The physicians have to understand how the drugs work and their
implications for patients. Each patient could potentially respond differently to different
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drugs, and therefore, each patient might need a different treatment even if he/she have the
same disease. The physician’s full understanding of the drugs will help eliminate any
unwanted side effects and mitigate any risks (Taylor, 2015). Thus, there are several
important components that go into administering effective treatments.
Diagnosis and treatment are two crucial components of a physician’s duties. The
oath sets a standard for the practice of medicine that can be utilized when giving
diagnoses and treatments. However, utilizing this oath in everyday situations becomes
more complicated as the medical field itself gets more complicated. In theory, doctors
should consider the Hippocratic oath everyday in their communication with and treatment
of patients, but it will become clear in the next chapters that the principles of the oath can
be forgotten in certain situations. It will become evident that the oath and the
development of the doctor-patient relationships can shift when new complications, such
as DTC advertisements, come into play.
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III. A Brief History of Drug Marketing
Now that the role of the physician has been established, I can analyze how DTC
advertisements can complicate that role. However, before discussing the drug
advertisements of today, it is necessary to give a brief history on how they came to be in
the first place. Much of the history of drug advertisements is connected with the FDA
because it has largely controlled the regulation of drug advertisements. The FDA is
responsible for many aspects regulating public health in the United States, including the
safety of food, cosmetics, and medications among others. With regards to medications,
the FDA is “responsible for advancing the public health by helping to speed innovations
that make medicines more effective, safer, and more affordable and by helping the public
get the accurate, science-based information they need to use medicines and foods to
maintain and improve their health” (Federal Drug Administration, 2016). Because the
FDA is responsible for regulating prescription drugs, it soon became responsible for
regulating the advertisements of prescription drugs.
The regulation of prescription drugs began in 1906 with the Federal Food, Drug,
and Cosmetic Act. The goal of the act was to provide consumers with the information
about the effectiveness of certain medicines. The act was expanded in 1938 and again in
1962. It was in 1938 that proving the safety and effectiveness of drugs before they could
be put on the market began. Prior to the provisions of this act and not until after World
War II in 1945, self-medication, that did not have any scientific backing, was a popular
practice. It was popular even more so than today because people were not seeking
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pharmacological treatment as prevalently. Instead, prior to World War II, people were
likely to self-medicate based off of unsubstantiated claims frequently found in newspaper
advertisements. An example can be seen in an advertisement for cocaine toothache drops
(Figure 3). The advertisement claims that the drops are an instantaneous cure, and people
could obtain them without knowing if they actually worked and without
recommendations from a physician. Shortly thereafter, drugs could only be obtained after
a physician wrote a prescription. As a result, pharmaceutical companies began to
advertise their products directly to physicians (Donohue, 2006). Prescription drug
advertising was largely under the control of the Federal Trade Commission (FTC) prior
to 1962, but in 1962, the FDA was granted jurisdiction over DTC advertisements
(Donohue, 2006; Frosch et al., 2010).

Figure 3. Example of a drug advertisement prior to the enactment of the Federal Food,
Drug, and Cosmetic Act in 1906 (Say Yes to Drugs?, 2014).
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Final guidelines for drug advertising were issued in 1969. The advertisements: 1.) could
not contain any information that was considered false or misleading, 2.) could contain a
“fair balance” of the risks and of the benefits of using the drug, 3.) could present facts
that are essential to the advertised uses of the drug, and 4.) must contain a summary of
the risks involved with taking the drug (Boden & Diamond, 2008). The provisions,
however, made no mention of advertising to the public (Donohue, 2006). The FDA does,
in fact, provide an explanation as to why.
According to the FDA, there had been no necessary federal ban on DTC
advertising because drug companies provided information about their products directly to
doctors and pharmacists. They did this through medical journals, continuing medical
education, sales calls, etc. (Abramson, 2004). It was not until the 1980s that some drug
companies began providing more information about drugs to the general public, rather
than to physicians, through advertisements (Background on Drug Advertising, 2015). In
1981, drug companies began advertising directly to the public and bypassing physicians.
The first print drug advertisement was published in Reader’s Digest by the company,
Merck, that was advertising a new antipneumococcal vaccine (Ventola, 2011). Not long
after, the first broadcast advertisement and print advertisements were put out by Boots
pharmaceuticals to promote a prescription pain reliever, Rufen (Donohue, 2006). Boots
was promoting a lower price of their version of ibuprofen as compared to Motrin, which
was produced by McNeil Consumer (Figure 4) (Ventola, 2011).
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Figure 4. Screen grabs from the first broadcasted drug advertisement by Boots pharmaceuticals
promoting their product, Rufen, a pain relieve (Scott, 2015).

As a result of these advertisements, the FDA was forced to review its policies. In 1985,
the FDA came to the conclusion that the these new drug advertisements would have to
follow the same stipulations, such as the fair balance of both risks and benefits and the
brief summary of potential side effects, which are outlined in the 1969 addendum to the
Federal Food, Drug, and Cosmetic Act. Because of these stipulations, drug
advertisements in the 1980s were largely print advertisements as the airtime was not long
enough to include all of the necessary information as required by the FDA (Ventola,
2011). Drug companies, clearly not satisfied with these restrictions, applied pressure on
the FDA to loose some of the restrictions (Abramson, 2004).
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In order to address the dissatisfaction expressed by the pharmaceutical companies,
the FDA held hearings in 1995 to discuss the regulations and potentially loosen its
restrictions (Ventola, 2011). Pressure from the pharmaceutical companies forced the FDA
to introduce new provisions for broadcasted advertisements in 1997 (Donohue, 2006).
The advertisements no longer had to include a brief summary of the side effects; they
only needed to include “major risks” and directives, such as a toll-free number, a print ad,
a website, or a physician, for consumers to access the entire summary of potential side
effects (Donohue, 2006; Ventola, 2011). Pharmaceutical companies quickly responded to
these new policy changes, nearly doubling their spending on television advertisements.
The amount of money invested into television drug advertisements climbed from $310 to
$664 million between 1997 and 1998. By 1998, the total amount of money spent on all
drug advertisements reached $1.3 billion. A majority of all spending for DTC
advertisements transitioned to television advertising after the policy changes, and the
1990s saw nearly 80 percent of prescription drug advertisements focus on the drug itself
rather than the medical condition (Donohue, 2006). The changes that took place resulted
in a shift where pharmaceutical companies took the place of the physicians’ diagnoses
and treatment choices.
From the aforementioned statement, it could be argued that patients are
consumers, and in fact, they are. However, should prescription drugs that treat serious
illnesses be advertised in the same light as groceries? As was discussed earlier, “A
Patients’ Bill of Rights’ was created in 1979. Patients have the right to full disclosure in
regards to their healthcare, but it begins to get complicated when the patient becomes the
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consumer. Where is the distinction made and what implications does it have in regards to
drug advertisements? As was mentioned earlier, the 1990s saw a dramatic increase in the
amount of information made available to patients. Not only was this information made
available through televised advertisements, but also through the increase in technology,
such as the use of personal computers and increased access to the Internet. Those gave
patients access to a lot more information in regards to their healthcare and
consequentially medical decision-making. It was also shown that in 1990, only about
one-quarter of Americans felt confident with medical leaders as opposed to three-quarters
in 1966 (Donohue, 2006). With this decline in trust and the increasing availability of
information, it was inevitable that patients would begin to become more involved with
their healthcare. It must be made clear that patients being involved in their healthcare are
not the issue. The issue stems from DTC advertisements exploiting the changes that were
occurring during this time, and any criticism of the advertisements was being ignored. It
is evident that the amount of information made available to the patients along with
expanding trend of patients becoming more involved in their care was responsible for the
increasing amount of drug advertisements. The industry now invests billions of dollars
into drug advertisements, and the criticisms of those advertisements are no longer being
ignored. Critics of DTC advertisements come from physicians, consumers, and even
some in the pharmaceutical industry (Donohue, 2006). There are concerns with whether
or not the facts presented in the advertisements are actually beneficial to the patient and
whether or not they are misleading patients. The advertisements have the potential to
discredit physicians if physicians choose to not prescribe the advertised drugs. This could
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be detrimental to physician-patient relationships and to the medical field as whole.
Therefore, it is necessary to analyze how DTC advertisements have changed the
healthcare industry, in what ways, and if there are any necessary changes that need to be
made.
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IV. Drug Advertisements Today
It seems as if everywhere we look, there is a new drug that is being advertised. What
are doctors’ moral obligations in providing the patient the best care they can while also
dealing with outside sources essentially telling them how to treat their patients? How are
doctors to respond to patients who insist on being prescribed a certain drug even if it is
not in their best interest? Furthermore, if doctors do prescribe those medications, do they
have some ethical obligation to ensure that their patients receive those medications
despite their increasing costs?
Before addressing the physician’s responsibility and DTC advertisements, the current
FDA regulations on prescription drug advertisements need to be discussed. The
regulations that were established in 1997 were not revisited until 2004 when the drug
Vioxx, nonsteroidal anti-inflammatory drug (NSAID) used to treat arthritis, acute pain,
and painful menstrual cycles was voluntary removed from the market (Frosch et al.,
2010; Federal Drug Administration, 2004). Vioxx was one of the most advertised drugs
in the United States from 1999 to 2004. The company that promoted the drug, Merck,
spent nearly $100 billion promoting it, with nearly $1 billion in revenue (Ventola, 2011).
In fact, Vioxx received Brand of the Year in 2001 as a result of the success of its
advertising (Jaramillo, 2006). However, it was later found that Vioxx was linked to an
increased risk of developing cardiovascular disease, and as a result, the drug was pulled
from the market in 2004. Despite this, in 2004, the FDA again loosened regulations on
DTC advertisements allowing print advertisements to only include a brief summary of the
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product rather than the complete prescribing information (Ventola, 2011). This led the
U.S. Senate leader in 2005, physician William Frist, to call for a two-year voluntary
moratorium on DTC advertisements for newly approved drugs (Donohue, 2006). The
purpose of the moratorium was to delay the time newly approved drugs were advertised
directly to consumers to allow physicians time to understand the purpose of the drugs
before they begin prescribing them to patients (Saul, 2005). In response to the proposed
moratorium, some pharmaceutical companies announced a voluntary moratorium, and
Pharmaceutical Research and Manufacturers of America (PhRMA), the pharmaceutical
manufacturers trade group, proposed suggested guidelines that companies could adhere to
with DTC advertisements. However, those guidelines were strictly voluntary, and it is not
obvious whether or not the companies have adhered to the moratorium. Ultimately, no
government regulations were put in place in regards to the moratorium (Ventola, 2011).
Perhaps, this is why there was not a decrease in the amount of money being spent on drug
advertisements after 2005 (Figure 5). In fact, as the amount of spending on DTC
advertisements increased, FDA enforcement of regulations regarding DTC
advertisements decreased (Figure 5). Several reasons are cited for this decrease, but the
two main reasons are the same amount of staff remain to review the drug advertisements,
despite the increase in number, and the FDA is underfunded (Ventola, 2011).
However, there was a decrease in spending of DTC advertisements from 2007 to
2008 because of the financial crisis that caused the economy to slow down, causing the
first significant decrease in spending since 1998 (Figure 5) (Ventola, 2011). There was
renewed interest on the issue in 2007 and again in 2009, but legislators failed to reach a
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consensus on DTC advertisements, and thus, it remains a polarized issue (Frosch et al.,
2010). The FDA plays a critical role in the regulation of DTC advertisements, but if it is
failing to enforce regulations, patients are at risk of receiving misleading information.
Legislators cannot adequately address the issue because it is such a divisive debate.

Figure 5. Top figure shows the amount of spending in billions on drug advertisements from 1998
to 2009. Bottom shows FDA enforcement of regulations regarding DTC advertisments. As
spending on drug advertisements increase, FDA enforcement decreases (Ventola, 2011).
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To provide clarity as to why DTC advertisements are so divisive, the positive and
negative components of DTC advertisements needs to be discussed. As can be seen in
Figure 6, Frosch et al. (2010) suggests that there is a conceptual framework that exposure
to DTC advertisements follows. When people are exposed to DTC advertisements, that
leads to prescription requests based off a variety of factors, including the age of the
consumer, gender, education, and medical history. However, the information in the
advertisements can be of either high or low quality, but regardless of the quality of
information, it results in clinical care.

Figure 6. A model showing the effects of DTC advertisements (Frosch et al., 2010).
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This is considered a positive effect, but one of the results is inappropriate prescribing i.e.
prescribing medications when it is unnecssary (Figure 6) (Frosch et al., 2010). The other
two outcomes: adherence to prescribed regimen and amelioration of undertreatment can
be seen as positive outcomes, but those outcomes are very dependent of the quality of
information presented in the advertisements, and the quality of the information presented
is part of the controversy. Thus, the end result of that exposure can vary depending on the
type of information patients receive.
First, I will discuss the arguments that supporters of DTC advertisements pose.
Some of those arguments include, but are not limited to, informs the patient, encourages
the patient to contact their physician, promotes patient-physician communication,
strengthens the patient-physician relationship, increases treatment for under-diagnosed
conditions, and reduces stigma associated with certain diseases (Ventola, 2011). Perhaps,
the most widespread argument for the use of DTC advertisements is that they inform and
educate the patients. According to Frosch et al. (2010), surveys have been administered to
patients and physicians, and more than half of physicians claim that DTC advertisements
have the potential to educate patients about various health conditions and treatments. In
regards to the public, 75% of respondents claimed they had an improved understanding of
various diseases and treatments, and 40% reported that they used the DTC advertisements
to guide their decisions regarding treatment regimens (Frosch et al., 2010). Furthermore,
proponents of DTC advertisements claim that the advertisements encourage patients to
visit their physician thereby increasing physician-patient communication and
strengthening the physician-patient relationship (Ross & Kravitz, 2013).
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Along with increased communication between physicians and their patients,
proponents of DTC advertisements claim that patients are more likely to follow their
prescription regime (Figure 6). The likelihood they will follow their prescription regime
is because the drug advertisements for the drugs they are taking will serve as reminders
(Ross & Kravitz, 2013). However, data for this is scarce or has mixed outcomes. For
example, Frosch et al. (2010) discuss a survey, nationally representative of the public, in
which 82% of respondents believed that the drug advertisements could help them follow
the physicians’ guidelines for the prescriptions, but only 23% of patients recruited in
waiting rooms said the advertisements would increase the likelihood of them taking the
drugs. Proponents also argue that drug advertisements are making patients more aware of
illnesses that could have gone unidentified and untreated (Royne & Myers, 2008). Thus,
it can be said that proponents of DTC advertisements believe the educational value of the
advertisements far outweighs any potential risks associated with the advertisements.
However, the opponents of DTC advertisements have various reasons as to why the risks
associated with DTC advertisements far outweigh any potential educational value.
The arguments against DTC advertisements directly counteract the arguments
made in support of them. Opponents of DTC advertisements believe that they interfere
with physician-patient relationships, increase the cost of medications, oversimplify
complex medical issues, and promotes the use of newer products over older, safer, and
cheaper alternatives (Kaphingst & Dejong, 2004). In regards to the physician-patient
relationship, there are physicians who feel that the advertisements lead to patients making
unnecessary, and even unwarranted, requests (Frosch et al., 2010). However, the
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evidence on the effects of DTC advertisements on physician-patient relationships is
conflicted. Frosch et al. (2010), report that 39% of physicians and 30% of patients
believed the advertisements had a negative effect on the physician-patient relationship
while an industry-funded survey found that 82% of physicians did not associate
physician-patient problems with DTC advertisement. However, in yet another survey,
89% of family physicians did not believe that DTC advertisements benefitted their
relationships with their patients. In fact, physicians are more likely to report negative
aspects of DTC advertisements than patients are because the advertisements promote
unnecessary medical visits and prescription requests. Despite this, one survey found that
up to 78% of prescription requests were filled thus leading to inappropriate prescribing
acts (Frosch et al., 2010). Not only is there inappropriate prescribing acts, but there is
also an increase in prescribing acts altogether (Ross & Kravitz, 2013). This cause an
overall increase in healthcare costs for the patient (Direct-to-consumer advertising under
fire, 2009). Thus, there is the question of whether or not the DTC advertisements are
actually benefitting the patients.
There are inherent risks involved when taking any medication, but if patients are
being prescribed drugs that are medically unnecessary, are they fully aware of the risks
involved? The answer to that question appears to be mixed. O’Donoghue et al. (2013)
state that the advertisements themselves do not have or have very little information in
regards to drug efficacy, and even if they do, patients have a difficult time understanding
that information or overestimate the efficacy of the drug. Kaphingst & Dejong (2004)
conducted a study in which participants were asked to answer true/false questions
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regarding the drug advertisements they had been shown. The authors found that the
chances of the participants answering correctly was lower when the questions involved
risk information as opposed to other information presented in the advertisement.
Furthermore, there was a lower chance of answering correctly if the information was
given in text, both with and without audio, as opposed to just audio. Therefore, it seems
that patients have the most difficulty comprehending the risks associated with advertised
drugs.
Lastly, another argument against DTC advertisements is that they result in
medicalization. Frosch et al. (2010) define medicalization as “the process by which
nonmedical problems come to be defined as treatable illnesses, thereby potentially
increasing unwarranted diagnoses.” Scholars argue that medicalization has resulted from
mass marketing and that the pharmaceutical industry has been the major driving force
behind medicalization. There is an argument that medicalization is actually beneficial in
that it reduces stigma around certain illnesses, but critics maintain that the boundaries
around illnesses are only widened to expand the drug market rather than improving health
(Frosch et al., 2010; Payton & Thoits, 2011). The process of medicalization may have
been an unforeseen consequence of DTC advertisements, but evidence regarding the
potential social benefits of the process is scarce.
The benefits and risks of DTC advertisements can be made more evident by using
drugs that are currently on the market as examples. It can help to begin with Humira.
Humira is a medicine that affects the immune system. It is a Tumor Necrosis Factor
(TNF) blocker that can be used to treat a variety of autoimmune conditions, including but
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not limited to rheumatoid arthritis, plaque psoriasis, and Crohn’s disease (Medication
Guide HUMIRA®, n.d.). Because of its capability to treat a variety of diseases, AbbVie
Inc., the company that makes Humira, spent nearly $357 million on advertising for this
product in 2015, which was the largest amount spent that year, and this made Humira one
of the most advertised drugs in the United States (Robbins, 2016a). The timing of the
large amount of spending on advertising is not surprising because the patent on Humira
will expire on December 31, 2016. When patents are set to expire, pharmaceutical
companies will raise the prices of the drugs in order to gain as much revenue as they can
before the patent expires. With the patent expiring, generic drugs can now be produced
and would often cost less than the brand name drug. However, the new generic drugs that
are produced in place of Humira will likely cost just as much as Humira did before the
costs of the drug began increasing because the companies that produce the generic drugs
will price the drugs just below the name-brand drug (which has been increased) (Rockoff,
2016).
The advertisement itself may seem harmless to those who view it. One current
advertisement shows a middle-aged woman packing and traveling to visit her family. The
voiceover claims, “This is Humira helping me go further” (Figure 7). What viewers do
not know is that this particular advertisement, known as “Go Further”, generated an
estimated $9.4 million in revenue for AbbVie (Bulik, 2016). This advertisement is only
one of 9 advertisements for the drug, but the other advertisements are targeted for a
variety of other diseases. This particular advertisement includes everything that is
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required by the FDA. It includes major side effects and a directive to visit another source:
a website and instructions to discuss Humira with a physician.

Figure 7. Advertisement for Humira (Bulik, 2016).

The website is displayed in white writing on a purple block across the bottom of the
advertisement throughout the duration of the advertisement; though, the size of the
website pales in comparison to the figures in the advertisement themselves. The major
side effects are spoken rather than listed like the website, but the side effects are not
displayed in the advertisement. This practice is not optimal as it is not always the easiest
way for people to retain information. For Humira, those side effects are lengthy and can
be very serious. They can include allergic reactions, blood and liver problems, and even
psoriasis (Medication Guide HUMIRA®, n.d.). Yes, the drug that advertises its
effectiveness in treating psoriasis can result in psoriasis for patients who have never had
it or worsen the condition for those who were previously diagnosed with the condition.
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The advertisement also briefly displays that financial help can be given to those who may
not be able to afford the medication, but there is never any mention about how much it
costs, without or without insurance. If Humira is such an essential drug for many
Americans, why is there a need to advertise in it the first place? Would doctors not want
to prescribe the drug in the first place?
Although makers of Humira spend the most amount of money advertising the
drug, Humira is not a drug that most Americans need. Perhaps that is why more money is
spent advertising it. Another health issue that affects many Americans is high cholesterol
levels and the various diseases associated with it. A study conducted by Niederdeppe et
al. (2013) found that DTC advertisements resulted in over-diagnosis of high cholesterol
and consequentially over-treatment of high cholesterol. The study collected data using a
nationally representative survey between 2001 and 2007. Questions from the survey
included TV viewing habits, cholesterol diagnosis, statin (HMG-CoA reductase
inhibitors) use, and other risk factors for coronary heart disease. Statins can block the
build up of cholesterol in the liver, reduce LDL cholesterol (a main cause of coronary
heart disease (CHD)), and reduce the risk of CHD. The authors also collected data on the
advertisements themselves.
The results from the study showed a positive association between DTC
advertisements, high cholesterol diagnoses, and statin use. The results were consistent for
both men and women. The authors make it clear that individuals who were at a relatively
low risk for future cardiac events primarily drove the results, and there were very little
positive associations between the DTC advertisements and those individuals at a
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moderate or high risk for future cardiac events (Niederdeppe et al., 2013). Furthermore,
there were negative associations between the advertisements and women diagnosed with
coronary heart disease. Of course, there are limitations to the study, which the authors
address, but overall, the results imply exposure to DTC advertisements results in a
diagnosis from physicians of high cholesterol in individuals who are at a relatively low
risk for future cardiac events. This, in turn, results in individuals taking statin drugs that
are unnecessary.
In 2011, Lipitor, a statin drug aimed at lowering cholesterol, became the highest
selling drug in the world generating over $125 billion in sales over 14.5 years (Ennis,
2011). That same year, the patent on Lipitor expired, which meant that generic versions
of the medication could now be prescribed (Roan, 2011). Regardless of the brand name,
statins are still being prescribed, despite some controversy. There is now evidence that
statin use increases the risk of developing type-2 diabetes. In 2012, the FDA warned
about these side effects and required the maker of Lipitor to include warnings about the
diabetes risk. However, the warning labels were implemented too late for some people,
and there is now a pending lawsuit against the maker of Lipitor (Lipitor Lawsuit:
Litigation for Statin Drug Linked to Diabetes, n.d.). Despite the evidence of serious side
effects and a lawsuit, there are doctors who are still prescribing statins and are receiving
money to do so. A study conducted by Dejong et al. (2016) found that 279,699 physicians
received 63, 524 payments, mainly in the form of meals, from the pharmaceutical drugs.
Rosuvastatin, common brand for Crestor (a statin), represented 8.8% of statin
prescriptions, and the authors found that those physicians who received one single meal

37

from the company promoting Rosuvastatin, prescribed Rosuvastatin more frequently than
other statin drugs. Thus, there is another issue with doctors promoting certain drugs as
well. If there is a shift from advertising more to the physician than to the patient, how
should physicians respond accordingly?
Although Lipitor is controversial, perhaps the most controversial drug currently
on the market is the EpiPen. The EpiPen came to be in the 1970s by a request from the
Pentagon because the Pentagon needed a way to deliver a nerve gas antidote. This drug
could alleviate the allergic reaction caused by exposure to nerve gas. Thus, it would be an
immediate defense for soldiers who were exposed to nerve gas (Reimann, 2016). The
EpiPen was officially introduced in 1980 and is used in the general public to treat lifethreatening allergic reactions with epinephrine (Rubin, 2016). The drug company Mylan
acquired the EpiPen in 2007, and at the time, only produced $200 million in revenue.
However, as can be seen in Figure 8, EpiPen annual sales have increased dramatically
(Koons & Langreth, 2015). Figure 8 shows the price increase through 2015. With the
increase in sales came the dramatic increase in price, over a 400% price increase (Rubin,
2016). The EpiPen itself only delivers about $1 worth epinephrine, but as of 2016, it cost
$600 to purchase (Koons & Langreth 2015; Rubin, 2016). It only cost $57 when Mylan
acquired the product in 2007. Koons & Langreth (2015) credit Mylan with utilizing
textbook branding as well as a public awareness campaign. Those campaigns include
television advertisements, but they differ from the previously discussed DTC
advertisements.
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Figure 8. Data from the first quarter of 2008 to the third quarter in 2015 showing an
increase in the cost of EpiPen (Koons & Langreth, 2015).

These new advertisements are called “unbranded” advertisements. These
particular advertisements inform the public about a medical condition and are paid for by
a company who sells a drug for said medical condition. These ads are not required to
disclose side effects; instead, they inform viewers to visit the website where they will
learn about the treatment options the company offers (Robbins, 2016b). While the
prevalence of these ads has varied, Mylan purchased nearly $15 million worth of airtime
for an unbranded campaign it launched in April 2016 (Robbins, 2016b). Mylan capitalize
with these advertisements because of the increased awareness of anaphylaxis reactions. In
2010, there were new federal regulations requiring patients who experienced severe
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allergic reactions to be prescribed two epinephrine doses. The FDA also changed label
rules that allowed the EpiPen to be marketed to anyone at risk as opposed to those who
had already experienced an anaphylaxis reaction (Koons & Langreth, 2015). As a result
of these efforts, in part by Mylan, the use of the EpiPen has grown 67% in the last eight
years (Koons & Langreth, 2015).
Mylan announced that it would release a generic EpiPen, but the price would still
be $300 per pack of two (Rubin, 2016). Although the increase in cost for EpiPen was the
result of different marketing tactics, the use of unbranded advertisements is a shift from
traditional DTC advertisements. Despite informing the public about different medical
conditions, they still direct people to websites that are sponsored by companies that sell
the products. Even though there can be benefits to informing the public about certain
medical conditions, patients should be aware as to who are the ones promoting those
campaigns because the underlying message could be more about the specific treatment
for the medical condition as opposed to the condition itself. Nonetheless, the use of
advertisements to increase use of a specific drug does not seem to be slowing down
because of the large profits companies receive, but it is interesting to note that DTC
advertisements are not found worldwide.
Currently, only the United States and New Zealand allow DTC advertising. The
reasons for this vary, but Guessous and Dash (2015) state that DTC advertisements have
pros and cons that are regulated differently in different countries. Furthermore,
constitutional factors and patient and population safety considerations also play a role. In
the United States, the First Amendment protects the right to free speech, including
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commercial speech (Guessous & Dash, 2015). In New Zealand, unlike other developed
countries, there was never any legislation that prevented the use of DTC advertisements.
Similar to the United States, there were calls to ban DTC advertisements. The New
Zealand government responded in 2003 calling for a complete ban on the advertisements,
but the necessary legislation was not successfully passed (Toop & Mangin, 2007).
Perhaps the biggest reason why there are different regulations regarding DTC
advertisements is the lack of data surrounding them (Guessous & Dash, 2015). Most of
the data published is based off of surveys and opinions rather than experimental evidence.
The interpretations of the results can, therefore, be subjective. Thus, there are various
reasons as to why other countries do not have DTC advertisements.
While New Zealand has been unable to completely ban DTC advertisements,
Europe has recently been looking to allow DTC advertisements. In 2002, the European
parliament began debating about DTC advertisements except for ones that advertised
drugs for diabetes, asthma, and AIDS. However, the proposal was rejected (Rutter &
Gilbody, 2008). The debate then became prominent again in 2007, and the European
Commission published a document that discusses the patients’ rights to information. This
document is significant because it discusses the Internet as a different means of providing
information. Indeed, the Internet user has to actively search for information before that
information is available to them. The European Commission is trying to make a
distinction between advertising and information (Velo & Moretti, 2008). This distinction
was important for the European Commission proposal in 2008 that was aimed at trying to
provide patients with “non-promotional” information (Rutter & Gilbody, 2008). A
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majority of the European Commission voted against the proposal (Direct-to-consumer
advertising under fire, 2009). Currently, the debate continues about whether or not to
allow DTC advertisements, and if the ban is lifted, there will be intense consideration
about what regulations will be in place and what those advertisements would look like.
Europe is not alone in its consideration for allowing DTC advertisements. South
Korea is also looking at allowing DTC advertising. Because of increased access to the
Internet, more people are utilizing it to learn more about health information. As a result
of the increased access to information, Suh et al. (2011) felt that it was necessary to
survey South Koreans on their attitudes toward DTC advertisements. In South Korea,
drug advertisements are regulated, but DTC advertisements for prescription drugs are
generally prohibited with the exception of “professional” health journals and drugs that
are considered a preventative measure for contagious diseases, such as AIDS, plague, and
typhoid fever. The authors surveyed 350 subjects and addressed four different areas
concerning DTC advertisements. Those are the consumers’ attitude towards DTC
advertisements, consumer preferences regarding regulation, consumers’ expectation
regarding the effects of the advertisements, and the types of credible advertisements.
Although 52 respondents were excluded for incomplete questionnaires, 61.8% of those
who responded felt that DTC advertisements were necessary, but only 43.3% felt that
they could trust the information provided by the advertisement. Although the respondents
felt that the advertisements could be potentially educational in regards to treatments and
disease awareness, they also felt that the advertisements could lead to a misuse or overuse
of the drug advertised. To conclude, the authors note that South Korea must take a
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cautious approach when it begins to discuss DTC advertisements and whether or not they
should be implemented.
Whether a country is just beginning to consider allowing DTC advertisements or
the issue has been debated for years, banning the advertisements is just as difficult and
contested a process as allowing them in the first place. In regards to the United States,
perhaps the biggest debate about whether or not the advertisements can be banned
altogether is the right to free speech argument. Advertising is considered “commercial
speech” and its protection under the First Amendment dates back to the 1970s
(Shuchman, 2007). The Supreme Court developed criteria, known as the “Central Hudson
Test,” to determine if a ban on commercial speech is allowed. The test determines
whether advertising is misleading, if a ban advances government interest, and if that
government interest can be reached by utilizing a less restrictive method like including a
label. That is, if having a ban does not fall in line with government interest, then a ban is
not necessary. One lawyer, who served as a chief counsel for the FDA from 2001 to
2004, said that because a doctor needs to intervene in the process of a patient acquiring a
prescription that, it alone should prevent any ban on DTC advertising. Furthermore, he
says that the drugs also have to be approved by the FDA before they can be put on the
market, and because of FDA approval, DTC advertisements should be allowed. However,
serious adverse side effects of a drug can be potentially unknown before there is
widespread use of the drug, and thus an advertising moratorium should be put in place to
allow for post-marketing surveillance (Shuchman, 2007). However, as was mentioned
earlier, it is very difficult for regulations to be put in place for a moratorium to exist.
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Although there is a need for post-market surveillance, a complete ban on DTC
advertisements is unlikely. Furthermore, some believe that if Congress does enact a ban
and it is overturned, then future attempts to control regulations on DTC advertisements
would fail (Shuchman, 2007). Any efforts to completely ban DTC advertisements would
have to be well thought out in a way that does not violate the First Amendment.
Ultimately, if there cannot be a complete removal of the advertisements themselves, then
careful considerations must be made in regards to how the advertisements could be
restructured in a way that eases opponents’ concerns.
Those who have studied DTC advertisements have several recommendations as to
how the advertisements can be improved. There have been suggestions to have an
independent agency that reviews the advertisements, but Guessous & Dash (2015) note
that the FDA already has an office that reviews and controls the content of the
advertisements. Because the agency is not independent, it is unclear whether or not there
is potential for interests to be corrupted. However, the FDA enforcement of their policies
on DTC advertisements has decreased over time. Royne & Meyers (2008) state that a
policy change in 2002 now requires the FDA to obtain legal approval in order to issue a
warning letter. This policy change has slowed the review process, and consequentially,
less letters were issued altogether. Perhaps, a separate office or more employees need to
oversee that the advertisements are still in compliance after a certain time period has
elapsed. Royne & Meyers (2008) also report that there were concerns with how the
advertisements are reviewed in the first place. The FDA does not have a consistent way
of prioritizing the advertisements nor are there any official standards for determining
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which ads would likely cause the most harm. It is evident that the FDA needs to fix its
review process in order to limit the number of advertisements that may contain false or
misleading information. In addition, as was mentioned earlier, the FDA is very
underfunded so there also needs to be steps taken in order to ensure that the FDA is
receiving adequate funding. So how can the advertisements themselves be improved?
There are several different ways in which DTC advertisements can be improved. One
of those improvements has to do with providing more information about the risks
associated with taking the drug. In a survey conducted by the FDA in 2002, 60% of
respondents did not think that DTC advertisements provided satisfactory information
about the risks (Royne & Meyers, 2008). Beyond just communicating the risks,
advertisements could also communicate the efficacy of the drug. O’Donoghue et al.
(2014) showed that adding efficacy information, especially quantitative information,
about a drug in the DTC advertisements for both print and television potentially increased
an individual’s knowledge of the drug. If the patients are more aware of the effectiveness
of the drug they wish to take, they may be more likely to make more informed decisions
in regards to the drug. Furthermore, the authors believe this could lead to improved
patient-physician communication because patients are more aware of both the benefits
and the risks and thus are more educated when talking to their physicians. This differs
from current advertisements that only relay risks rapidly on television advertisements.
In addition to balancing benefit and risk information, improvements need to be made
on the way the information itself is presented. Information in television advertisements
should be presented in “consumer-friendly” language (Kaphingst & DeJong, 2004). That
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means that considerations must be made in regards to the literacy level of the recipients
of the advertisements. In addition to consumer-friendly language for television
advertisements, “plain language” should be used in print advertisements. The reading
difficulty of the advertisements should be no higher than an eighth grade level, which is
the reading level of the average American adult (Kaphingst & DeJong, 2004). So not only
should DTC advertisements include more information in the first place, they should
include information that is clear and easy to understand for patients with different
education levels. This does not mean that the information presented will be less precise.
Doctors have to find ways to present complex information in simple ways to their
patients, and creators of drug advertisements should be challenged to do the same.
Perhaps, by even working closely with physicians, creators of drug advertisements can
find the best way to communicate the risks of a drug without compromising any specific
and important information.
Lastly, there are suggestions about the way in which the advertisements are presented
can be improved. That is, the way medical conditions and the treatment for those medical
conditions are portrayed can be improved. Guessous & Dash (2015) state that most DTC
advertisements portray medical conditions and their treatments in a very superficial,
perhaps even glamorous, way. A study conducted by Frosch et al. (2010) showed that
advertisement narratives for treatments for cardiovascular disease shifted perceptions of
the actual cause of the disease. Participants were led to believe that high cholesterol was
primarily caused by hereditary factors, thus reducing the need for lifestyle change. The
authors suggest that there needs to be more scrutiny about the narratives used to show the

46

effectiveness of the drugs. Frosch et al. (2010) claim that less time is spent on the risks of
a drug while the benefits are discusses intermittently throughout the advertisement. Thus,
there needs to be more information about the risks and the effectiveness of the drugs. In
addition, Kapingst & DeJong (2004) suggest that the advertisements, if they are really
there to educate consumers, should also provide information about symptoms and other
risk factors for the advertised disease. Essentially, the advertisements should present
more accurate depictions of what the disease looks like.
A somewhat unconventional idea, but one that could mitigate some issues, is a
“Patient/Consumer television control device” as suggested by Guessous & Dash (2015).
This device would allow consumers to make an individualized and informed decision
about whether or not they want to watch TV with DTC advertisements. The authors state
that this would not only respect the First Amendment, but it would also respect the
individual choices made my consumers. Furthermore, they acknowledge that now it is
common practice for TV and Internet content to be profiled, and that this same practice
could be applied to health related content as well. However, in regards to the Internet, this
policy could be tricky as there are currently no regulations regarding online drug
advertisements because they are a lot harder to control and regulate as the Internet
surpasses boundaries established by different countries (Khosla, P. & Khosla, A., 2011).
The issue of DTC advertisements is complicated with patients’ increased use of the
Internet. Patients understandably want to know more about and become more involved
with their healthcare, and this medical value is called patient autonomy. Whether or not
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patient autonomy inhibits or helps with physician-patient relationships will soon be
discussed.
The increased role of the patient participation in healthcare was discussed briefly in
Chapter III. The idea of patient autonomy itself is a relatively new idea in healthcare. It
was not until 1980 that a revision in the American Medical Association Code of Ethics
explicitly stated physicians are required to respect patients’ autonomy. Furthermore,
medical education is placing greater emphasis on physician-patient relationships that
focus on shared-decision making that respects patient autonomy (Magnezi et al., 2014).
Patient autonomy itself is defined as “the patient’s right to involvement in the discussion
and decision-making process during consultation.” In addition, it is the ability for the
patient to have discussions without being heavily influenced by any healthcare providers
(Agarwal & Murinson, 2012). There are several reasons as to why patient autonomy has
become more prevalent in healthcare, including an increased rate of chronic illnesses, the
patients’ rights movement, and increased Internet usage (Arney & Lewin 2013). Because
of increased Internet usage, there are some patients, particularly those who are educated,
who will have an increased medical knowledge. However, this is not the case for
everyone. Although more people have access to the Internet and can therefore learn more
about their medical conditions, it does not always mean that patients fully understand
their medical conditions. Thus, there is some disparity with how much medical
knowledge patients actually know despite the increase in Internet usage. In addition, the
Internet does not always present accurate and correct information, and not every patient
will know how to screen for correct information. Therefore, physicians have to respond
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appropriately in order to develop and maintain physician-patient relationships that serve
the best interest of the patient.
Thus, new models are being created to address the increased amount of information
patients have, before they visit their physicians. One model proposed by Agarwal &
Murinson (2012) addresses patient value, patient autonomy, and patient knowledge. The
authors suggest that by utilizing this model, physicians can better interact with their
patients. For example, if the patient knowledge is low, then the physician can provide
more medical knowledge to the patient and in a greater context. In addition, physicians
can direct patients to more reputable sources. How does this model come into play when
the information the patient has is from DTC advertisements? How should doctors respond
to a patient’s demands for a specific drug they saw advertised?
One study conducted by Arney & Lewin (2013) looks directly at the portrayal of
physician-patient relationships in DTC advertisements. The authors were trying to
identify how doctor-patient relationships were depicted in drug advertisements and then
also get an opinion of the types of relationships the patients themselves wanted. They
analyzed DTC advertisements directly and then also conducted interviews with 36
inviduals. The researchers identified four different physician-patient relationship models
while interviewing respondents to examine how consumers receive DTC advertisements.
Those four models are physician-as-confidant, consumer-and- supplier, scientist-andspecimen, and patient-as-autocrat. The physician-as-confidant model shows a high
emotional connection between the patient and the physician while the consumer-andsupplier showed a relationship based off of negotiation. These are the two models that are
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predominantly found in DTC advertisements. The consumer-and-supplier model was
found in 30% of DTC advertisements. The respondents viewed the physician-asconfidant model as an idealized relationship but one that they did not actually have. The
last two model types are not found in DTC advertisements, but respondents in the
interviews mentioned them. The scientist-and-specimen model places the physician in
complete control, and this model was preferred by 39% of respondents. The patient-asautocrat model is characterized by patients questioning their doctors and patients often
seeking health information on their own. This model was identified by 25% of
respondents. Interestingly, women preferred this model more while men preferred the
scientist-and-specimen model more. Despite the four different models, respondents
primarily described the physician-as-confidant model as an ideal rather than what they
actually have. The authors suggest that the pharmaceutical companies are capitalizing on
these types of advertisements because it encourages patients to discuss treatment options
with their doctors. Although this is considered a good thing, it is solely focused on the
specific treatment advertised, which may not necessarily be in the best interest of the
patient.
Although there are different models and different ideas of how physicians can
respond to patients’ increased medical knowledge and demands for different treatments,
how physicians put that into practice can vary. Getting insight from a currently practicing
physician can shed some light on how physicians should respond to their patients and
what should be done with DTC advertisements as a whole. Therefore, the next section
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contains the summary of an interview I conducted with Dr. Robin Dickinson, who
practices medicine in Denver, Colorado.
Dr. Dickinson practices family medicine. More specifically, she practices what is
called community supported family medicine or direct primary care (DPC). She provides
medical services to her patients, who pay a monthly membership fee. DPC differs from
concierge medicine because each DPC practice fits the needs of the population it is
serving. Thus, her practice is especially equipped for providing care to patients who do
not have insurance and cannot otherwise afford healthcare. Dr. Dickinson first wanted to
be a doctor when she was 6 years old. Growing up in an abusive home, she did not realize
that being a doctor was a possibility, but it was her mother who told her that she could.
She attended the University of Denver for her undergraduate education, and she went to
the University of Colorado for medical school. At first she thought she wanted to be a
pediatrician because of her experiences growing up, but she soon realized that family
medicine is what she was the most passionate about. Through family medicine, she could
address all aspects of a patient’s life and provide the best possible care. She completed
her residency in Pueblo and soon began working at a family medicine practice. It was
while working at that practice that she thought about opening her own practice; although,
at first, she never thought that she would. While at that practice, she soon realized that
there were some constraints that she felt could hinder the care that she wanted to provide
to her patients. Thus, she took the necessary steps to open her own practice.
Because of her unique perspective on medicine, I believe that she could provide
some insight into DTC advertisements and how they are affecting doctor-patient
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relationships. She first discussed how at the old practice, drug representatives would
come in to talk to the doctors and would always provide free lunch. She said that the
doctors were essentially trained to view the drug representatives as nice people and to
like the drug representatives. That is, the physicians and staff who had been there longer
than she had told her that they want her to like them; no one ever did anything differently.
However, when she noticed that one of the physician assistants (PA) did not attend these
lunches, she was curious as to why. This PA said that the representatives were using
manipulative tactics to get the physicians to use their drugs and that it could look bad to
the patients if they were receiving these free lunches from drug representatives. This was
prior to the new law passed under the Affordable Care Act, the Sunshine Act. The
Sunshine Act requires all pharmaceutical and medical device companies to report any
payments that doctors receive to the public if the amount is over $10 (Cochran, 2014).
After the law was passed, the practice actually voted on whether or not it should get rid of
lunches. It decided that each doctor could individually decide whether or not they wanted
to attend, and if not enough people were attending, the problem would be readdressed.
Dr. Dickinson said that as far as she knew, she was the only physician who sat out those
lunches.
The aforementioned narrative is what fueled Dr. Dickinson’s desire to open her
own practice. Most of the patients she sees now are of a lower socioeconomic status.
Thus, she found that patients requesting specific prescriptions were not as frequent. In
fact, Kaphingst & DeJong (2004) reported that for print advertisements, “college-level
reading ability would be needed to read the average brief summary section.” So even
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though print advertisements are more accessible than television advertisements for people
with a lower socioeconomic status, they would still be unable to comprehend the risks
associated with taking certain drugs because the language used to describe the risks are
above their reading level. This is why Dr. Dickinson makes it a point to thoroughly
discuss with every patient why he/she came into see her because she recognizes that her
patients are not going to be knowledgeable about their medical conditions or about the
risks associated with certain drugs. Thus, she makes it a point to thoroughly educate her
patients as much as she can about their conditions and about the drugs that they will use
to help with their medical conditions. If a specific drug is requested, she goes through the
entire process of why the patient may or may not need that drug. She emphasizes that her
appointments are just as much about educating the patient as they are about treating the
patient.
Thus, in regards to DTC advertisements, Dr. Dickinson says that the practice as a
whole should be put to a stop. Even if changes are to be made, the pharmaceutical
companies will most likely find ways around them. Instead, she believes that physicians
should look towards educating their patients about the reasons for their visits and also
educate patients about the drugs that they may be requesting. She emphasizes that
treating a patient is about building a relationship and establishing trust with the patient in
order to fully disclose health information, which will lead to the best treatment. Even if
that means spending more time with a patient that may seem necessary, it has to be done
in order to serve the best interests of the patient.
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Of course, this is only the opinion of one physician, but Dr. Dickinson brings up
some valuable points. Although I, myself, am not sure of what type of practice I would
like to open or even the field of medicine I want to go into, I admire the way that Dr.
Dickinson treats her patients. I especially like her emphasis on education and really
working with patients to address their illnesses. Spending more time getting to know and
educating patients is essential to providing them with the best possible care. Moving
forward, with an increase in medical technology, the advent of personalized medicine and
with an increase access to medical knowledge, DTC advertisements may eventually
become irrelevant.
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V. Personalized Medicine
Personalized medicine is the “selection of treatment best suited for an individual,
involves integration and translation of several new technologies in clinical care of
patients” (Jain, 2015). The term itself is used interchangeably with several other terms,
including but not limited to, “precision medicine”, “individualized medicine”, and
“stratified medicine”. These terms were initially used in specific contexts but have
merged together to generally identify the same thing (Abettan, 2016). Advances in
chemistry, biochemistry, and genetics, among others, have allowed for personalized
medicine to formulate. With the advent of genomics, the human genome project had been
completely sequenced by 2001. Following the completion of that project began the
ENCODE project (Encyclopedia of DNA Elements) which aimed to described all of the
functional elements in the human genome (Jain, 2015). The results of these projects
provided scientists with important insights into the functions of genetics and DNA, and
how manipulations in the genetics code can result in various diseases. Being able to
pinpoint how a disease was caused in one given individual and finding techniques to treat
this particular disease on a molecular level using various molecular biology techniques
lead to the birth of personalized medicine.
Since then, there is more emphasis being placed on researching personalized
medicine. In 2015, President Obama announced that there would be new funding, $216
million worth for the fiscal year 2016, for the National Institute of Health, the National
Cancer Institute, and the FDA. The Precision Medicine Initiative has short-term and long-
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term goals. The short-term goals include more research on personalized or precision
medicine for cancers while the long-term goals are focused on bringing personalized
medicine to a large scale for healthcare (U.S. National Library of Medicine, 2015).
Much like the field of medicine has evolved over times, doctor-patient
relationships have also changed. While direct-to-consumer drug advertisements currently
serve to complicate doctor-patient relationships, personalized medicine has the potential
to further complicate this precious relationship. Of course, there is also the potential for
personalized medicine to strengthen doctor-patient relationships. More specific
information about patients will be known by physicians, and it is what physicians do with
that information that can either strengthen or weaken their relationships with patients.
There is the potential for physicians to only address their patients by the information they
receive. That is, patients will only be seen as their genetic information rather than as a
whole person. With the specificity that personalized medicine offers, physicians have to
be aware that regardless of the specific problem they are addressing, it still impacts the
patient as a whole. Therefore, physicians still have a responsibility to treat and care for
their patients as a whole despite the specificity that personalized medicine offers.
With that in mind, DTC advertisements will add another layer of complexity to
doctor-patient relationships but in the context of personalized medicine. DTC
advertisements can continue to be misleading about what personalized medicine has to
offer. Although personalized medicine has the potential to radically change medicine, its
full potential must not be overstated. There are still limits to personalized medicine, and
patients have to be aware of that. However, as medicine continues to move towards
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personalized medicine, pharmaceutical companies could further utilize DTC
advertisements to capitalize on the advantages of personalized medicine for their own
personal gain.
Direct-to-consumer advertisements have evolved with the field of medicine.
Although the field of medicine itself has been around significantly longer than DTC
advertisements, the two now coexist. The field of medicine will most likely continue to
evolve, and it will be interesting to see whether or not DTC advertisements evolve with
it. The direction that medicine seems to be heading is toward personalized medicine. If
DTC advertisements are altered, or perhaps removed altogether, as a result of
personalized medicine, what implications does that have on doctor-patient relationships?
Does personalized medicine itself add to doctor-patient relationships?
It seems that because of the significant funding allocated for personalized
medicine there would be benefits for the practice and many believe that personalized
medicine has the potential to revolutionize healthcare. However, there are new concerns
with whether or not funding will remain in place because of the new Trump
administration. One article states that there is bipartisan support for personalized
medicine, but this still does not completely ease concerns, as the administration could
potentially not agree with either party. A 2017 appropriations bill regarding funding for
the Precision Medicine Initiative was not passed, but rather, continuing resolutions that
were established prior for funding were put in place until March 31, 2017 (Ray, 2016).
This is not completely unusual during an election year, but some are worried that major
changes will happen to the 2017 budget, which could have a significant impact on
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ongoing research. In addition, some worry that funding will be cut entirely because some
Republicans might see it as another effort to heighten Obama’s legacy (Ray, 2016). Thus,
it remains to be seen if current research, as funded by the federal government, will
continue.
Personalized medicine can potentially be beneficial to many people. Abettan
(2016) discusses how it could potentially be a paradigm shift in medicine. Advances in
genetic knowledge can allow for more accurate prescriptions for patients. That is,
prescriptions can be produced that specifically fit an individual’s genotype, and in turn,
adverse side effects can be greatly reduced. This would require active participation by
pharmaceutical companies because they are the ones producing more effective medicines
with fewer side effects (USFDA, 2013). However, if pharmaceutical companies are not
willing to invest in personalized treatments, then the process could be hindered.
Pharmaceutical companies would have to find new drug therapies that replace existing
and profitable ones, which may not appeal to some companies (Jameson & Longo, 2015).
Fortunately, it seems that more companies are wiling to invest in more personalized
medications. For example, a drug used by HIV patients, Abacavir, is safe for all but 6
percent of patients who develop serious allergic reactions. Researchers found that a single
genetic variant was causing the reaction and now HIV patients are screened for that
genetic variant before they are prescribed Abacavir (Abettan, 2016). Personalized
medicines also attempt to give patients the right drugs at the right time (USFDA, 2013).
To go a step even further, supporters of personalized medicine believe that it can go from
reactive to preventative medicine. By utilizing genetic testing, doctors can earlier predict
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the risk for some patients of developing a specific disease (Abettan, 2016). As more of
these genetic tests become available, it is likely that pharmaceutical companies will begin
to put their own genetic tests on the market. However, the testing as well as the therapies
that are done needs to be safe and effective, and the FDA is implementing new research
regulations and standards in order to ensure this (USFDA, 2013).
As with any change in medicine, there are going to be some who do not see the
benefits or have serious questions about personalized medicine and what it means for the
field as a whole. One concern with personalized medicine is the cost. One study claims
that healthcare costs would be reduced with personalized medicine if the focus is on
prevention over therapy, but other studies have shown that genetic information can lead
to an increase in physician visits which results in more laboratory tests and increases
patient anxiety (Joyner & Paneth, 2015). Those increase in physician visits and laboratory
tests could potentially lead to the patient paying more to cover those costs. In addition,
there is also concern with the cost of the therapies themselves. Currently, new, targeted
cancer drugs can cost up to $100,000 a year (Joyner & Paneth, 2015). However, it can
reduce the likelihood of treatment failure thus resulting in less money spent over the long
term. Also, there is a likelihood for safer clinical trials which reduces the risk of serious
side effects which again, can reduce healthcare costs in the long run (Shoaib et al., 2016).
It is understandable that there are concerns with the costs associated with personalized
medicine, and it is a concern that would have to be monitored moving forward.
Not only are there concerns with what costs might be associated with personalized
medicine, there are also some ethical concerns. One of them relates access to genetic
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information. There is the possibility that individual’s genetic information would be
available to a wide number of people (Jain, 2015). It is also possible that patients would
only be seen as genetic information as opposed to whole people who have differing
opinions and emotions. This is worrisome for some physicians who argue that it could
lead to a technical communication with patients as opposed to individualized
communication (Abettan, 2016). There is also concern with the information patients
actually receive from any genetics tests they have done. There is a potential for there to
be incidental findings. In one survey, a majority of patients wanted to be asked what
information they would like to receive. That is, some patients do not want to know about
some information that is found in the genetic tests, and physicians have a responsibility to
respect their patients’ wishes (Shoaib et al., 2016).
In addition to the aforementioned concerns, there are also some ethical concerns
with the information found during genetic tests and what it could mean for healthcare as a
whole. There is concern with who would have access to patients’ genetic information and
how it would be used. To address these concerns, the U.S. Congress passed the Genetic
Information Nondiscrimination ACT (GINA) in 2008. This legislation prevents insurance
companies from using a person’s genetic information in determining eligibility or
premiums, requiring or requesting a genetic test, or employers using genetic information
to make employment decisions. However, there are worries that the bill would be
difficult to enforce, and it does not discuss long-term care insurers or life insurers. The
Affordable Care Act would prevent insurance companies from using preexisiting
conditions, whether they are genetic or not, to establish premiums (Jain, 2015). If
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companies were found to be in violation of the act, they will have to pay a fee as a well as
take measures to fix the mistake (Shoaib et al., 2016). Prior to the Affordable Care Act,
insurance companies could deny individuals with preexisting conditions. Moving
forward, this is something these are factors that will need to be considered when the laws
governing healthcare have the potential to change at any time.
There are significant implications personalized medicine can have on healthcare,
but more people need to actually know about the practice before some of those
implications can be understood. Now, a multitude of top institutions are creating
campaigns to market advances in personalized medicine (Wolinsky, 2015). These
advertisements can potentially be very harmful to patients because patients can misuse
the test, misinterpret the results, and not follow-up on the results with a physician.
Furthermore, there is concern that the DTC genetic screening tests may not be as accurate
as laboratory tests (Jain, 2015). That is, laboratory tests are done by trained professionals
with access to much more precise as sophisticated tools as opposed to the DTC genetic
screening tests performed at home. Much like DTC advertisements, there needs to be
regulation by the FDA for DTC genetic testing. One review of marketing genomic
campaigns found that many advertisements were very close to being deceptive and
potentially unethical (Wolinsky, 2015). In Europe, a survey was conducted which showed
that a majority of clinical geneticists do not believe that DTC genetics tests are clinically
useful and that certain test should be more carefully regulated or banned altogether. They
believe that DTC genetics tests should be required to undergo the same procedure that
DTC pharmaceuticals do for market introduction (Jain, 2015). Ultimately, it is clear that
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careful consideration needs to be put into advertisements for DTC genetic screening tests.
Even institutions themselves have to be considerate of the claims they are making in
regards to personalized medicine and provide full disclosure as to whether or not their
therapies will benefit a particular patient.
With that in mind, it is evident that personalized medicine will have some impact
on doctor-patient relationships. As was mentioned earlier, patients are taking a more
proactive role in managing their healthcare because of their increased access to the
Internet for information. Of course, this does not always mean patients fully understand
the information that they are being presented, but there is the potential for patients to
become more knowledgeable about their healthcare. If patients do have an increased
medical knowledge, they may want treatments and/or therapies that are specifically
designed for them or that may not be as harmful. On the other hand, some patients may
not be as actively involved in their healthcare. Regardless, it is essential for physicians to
remember that an important part of personalized medicine is caring for the whole person,
including the patients’ views and lifestyles in addition to their health (Pokorska-Bocci et
al., 2014). Pokorska-Bocci et al. (2014) maintain that clinical medicine will continue to
be a process of choosing the best care for the patient and that biomedical sciences will
help refine the process. The best care given still has to be what is the best suited for the
patient’s health, preferences, and circumstances; that is determined by fostering a
dialogue between the patient and the physician. Thus, personalized medicine can only be
achieved when all aspects of the patient are taken into consideration (Abettan, 2016). If it
is, personalized medicine has the potential to strengthen physician-patient relationships.
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Patients would only be given medications that are guaranteed to better the patient, and
patients would be more willing to listen to their physician and follow the treatment
regimen (Shoaib et al., 2016). However, this is still dependent on a dialogue between the
physician and the patient. Ultimately, even though personalized medicine may become
the future of medicine, it is still dependent on an established relationship between the
physician and the patient that determines the best suitable treatment for that patient. Even
as personalized medicine continues to advance, physicians should still view their patients
as patients as opposed to test subjects whose only purpose is to advance the field.
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Final Thoughts
The field of medicine has a long history, and beginning with the Hippocratic
Oath, it has developed and progressed to the practice that we recognize today. It has
evolved from a practice based on primarily superstitious and religious beliefs to one
guided by science and scientific research. The advent of technology has further evolved
the field of medicine. With the completion of the human genome project, medicine has
the potential to revolutionize how we treat patients. The field of medicine is unlike any
other, and those who choose to enter the field have a tremendous responsibility.
Unfortunately, there are many other factors that have influenced the field that have
caused some physicians to stray away from what it really means to be a physician. Of
course, this is not the case for every physician, but it has become widespread enough that
it is something that needs to be addressed. One of those factors is DTC advertisements.
Beginning my research on DTC advertisements, I was not really sure what I
would find. I was not even sure that I was particularly against them or what they really
had to do with doctor-patient relationships. However, it soon became clear that they do,
in fact, have a significant impact on the healthcare field and can be potentially disruptive
to doctor-patient relationships. While I maintain that DTC advertisements should be
eliminated altogether because of the overall negative impacts they can have, it does not
seem like a realistic action that will happen any time soon. Therefore, I think that it
becomes the duty of the physicians to ultimately negate them and decide what is best for
their patients. It is necessary for physicians to develop relationships with their patients
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and develop an understanding that patients are so much more than their medical
condition. This becomes increasingly important with patients’ increased access to
healthcare information because of easier access to information found on the Internet.
Physicians will have to learn to navigate and work with their patients to determine which
information is actually beneficially to them.
It may seem that I am being especially critical of physicians, but in today’s world,
where pharmaceutical companies’ sole purpose is to make a profit, physicians are
challenged to rise above that notion and care for their patients regardless of any financial
profit. Physicians have been given a special role in society to care for people, and they
should be taking that role seriously. Physicians should be working closely with patients,
educating them about their illnesses. Establishing relationships with patients makes it
more feasible to physicians to successfully treat them
After completing all of my research, I feel confident working towards my goal
that I have a better understanding of the medical field and the role of the physician as a
whole. Although it might not be easy, I believe that being the successful physician is
possible. Establishing relationships with patients and educating them is the best way to
help treat them. Included in that is treating patients with the understanding, compassion,
and respect that they deserve. The medical field and even the pharmaceutical industry
will continue to change and evolve, but the most important thing to remember is,
ultimately, what the role of the physician should be
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